Immunic (IMUX) Other Operating Expenses (2014 - 2022)

Immunic (IMUX) reported Other Operating Expenses of $33.0 million for Q4 2022, up 91.13% sequentially from $17.2 million in Q1 2021.

Immunic (IMUX) Other Operating Expenses (2014 - 2022) Analysis & Trends

Immunic (IMUX) has 6 years of Other Operating Expenses data on file, last reported at $33.0 million in Q4 2022.

For the quarter ending Q4 2022, Other Operating Expenses changed N/A year-over-year to $33.0 million; the trailing twelve-month figure through Sep 2023 stood at $33.0 million (changed N/A YoY), and the FY2022 full-year result was $33.0 million, up 91.13% from the prior year.
Other Operating Expenses advanced to $33.0 million in Q4 2022, from $17.2 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $33.0 million in Q4 2022 to a low of -$12.2 million in Q1 2018.
A 4-year average of $4.9 million and a median of -$1.2 million in 2018 frame the typical range for Other Operating Expenses.
Peak annual rise in Other Operating Expenses reached 47.81% in 2019, while the deepest fall reached 47.81% in 2019.
Tracing IMUX's Other Operating Expenses over 4 years: stood at -$1000.0 in 2018, then sank by 636800.0% to -$6.4 million in 2019, then surged by 370.84% to $17.2 million in 2021, then surged by 91.13% to $33.0 million in 2022.
Business Quant data shows IMUX's Other Operating Expenses at $33.0 million in Q4 2022, $17.2 million in Q1 2021, and -$6.4 million in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immunic	11.03 Mn	11.03 Mn	-

Download Data